Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Ph...
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
About this item
Full title
Author / Creator
Sezer, Zafer , Pavel, Shaikh Terkis Islam , Inal, Ahmet , Yetiskin, Hazel , Kaplan, Busra , Uygut, Muhammet Ali , Aslan, Ahmet Furkan , Bayram, Adnan , Mazicioglu, Mumtaz , Kalin Unuvar, Gamze , Yuce, Zeynep Ture , Aydin, Gunsu , Kaya, Refika Kamuran , Ates, Ihsan , Kara, Ates and Ozdarendeli, Aykut
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized, controlled, double-blind, phase 2 study. Forty-two participants included in...
Alternative Titles
Full title
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4c74fde40dfc40e3a45a1fce48df4d77
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4c74fde40dfc40e3a45a1fce48df4d77
Other Identifiers
ISSN
2076-393X
E-ISSN
2076-393X
DOI
10.3390/vaccines12020140
